Travoprost Shortage: What Providers and Prescribers Need to Know in 2026

Patients with glaucoma or ocular hypertension who rely on travoprost (Travatan Z) for intraocular pressure (IOP) control occasionally encounter difficulty filling their prescriptions despite the absence of a formal FDA drug shortage. This briefing summarizes the current travoprost supply landscape, therapeutic substitution options, and practical steps you can take to reduce treatment interruptions for your patients.

Current Supply Status: No Active FDA Shortage

Travoprost ophthalmic solution 0.004% is not listed on the FDA's current drug shortage database as of 2026. The U.S. market is served by multiple manufacturers including Sandoz (brand Travatan Z), Mylan, Lupin, Apotex, Glenmark (ionic buffered generic launched 2024), Sagent (launched 2025), and Alembic (FDA final approval December 2025). Despite national supply adequacy, patient-level access problems arise from pharmacy-specific stocking decisions and single-supplier dependency at retail chains.

Understanding the Generic Travoprost Landscape

Prescribers should be aware of a clinically relevant distinction in the generic travoprost market: the preservative system used.

Travatan Z (sofZia-preserved): The brand uses sofZia, an ionic buffered preservative system that is gentler on the ocular surface than benzalkonium chloride. Particularly beneficial for patients with dry eye or ocular surface disease.

BAK-preserved generics: Many generic travoprost products use benzalkonium chloride (BAK), which has been associated with conjunctival inflammation and tear film disruption in susceptible patients. For most patients, this difference is clinically insignificant.

Ionic-buffered generics (newer): Glenmark's and Alembic's generics use the ionic buffered formulation — therapeutically equivalent to Travatan Z including the gentler preservative system, at generic pricing.

For patients with documented preservative sensitivity, specifying 'Travatan Z' or 'ionic buffered formulation' in your prescription — or noting 'brand medically necessary' — can help ensure they receive the appropriate product.

Formulary and Insurance Considerations

Travoprost falls across a wide range of formulary tiers depending on the plan. Key points for prescribers:

Step therapy: Some commercial plans and Medicare Advantage plans require step therapy through latanoprost (typically the most formulary-preferred prostaglandin) before authorizing travoprost. Document trial and inadequacy if initiating travoprost directly.

Quantity limits: Most plans restrict travoprost to one bottle (2.5 mL) per 25–30 days. Patients should time refill requests accordingly.

Medicare Part D: Generic travoprost is generally covered under Part D. Eye care providers account for a disproportionate share of brand-name prescribing in Medicare; defaulting to generic when clinically equivalent can reduce patient cost burden significantly.

Prior authorization: Brand Travatan Z may require prior authorization on many plans. For patients with ocular surface disease who require the sofZia formulation, have documentation ready for the PA submission.

Therapeutic Substitution Options When Travoprost Is Unavailable

If a patient cannot find travoprost and needs an urgent bridge, the following within-class options are appropriate:

Latanoprost (generic Xalatan): First-line substitution. Same mechanism, once-daily evening dosing, IOP reduction of 7–8 mmHg, lowest cost (~$8–15 with discount card). Widely stocked at virtually all pharmacies.

Bimatoprost (generic Lumigan): May provide 1–2 mmHg greater IOP reduction. Appropriate for patients with higher target IOP needs. Also once-daily.

Tafluprost (generic Zioptan): Preservative-free option for patients with significant ocular surface disease or preservative allergy. Single-use vials.

Important: Never combine two prostaglandin analogs. Concurrent use decreases IOP-lowering efficacy and may paradoxically raise IOP. Clearly instruct patients to stop travoprost when starting an alternative prostaglandin.

Helping Patients Locate Travoprost in Stock

When a patient reports inability to find travoprost, directing them to medfinder for Providers is an efficient option. medfinder calls pharmacies in the patient's area and identifies which ones can fill the prescription — saving clinical staff time and ensuring continuity of care. Results are texted directly to the patient.

Adherence Risk and the Clinical Importance of Uninterrupted Treatment

Medication adherence is the single most modifiable risk factor in glaucoma management. Patients who cannot fill their prescription — even temporarily — are at risk for IOP rebound and disease progression. Glaucoma patients already demonstrate higher rates of cost-related non-adherence compared to other chronic disease populations. Proactively discussing cost, pharmacy access, and alternatives at each visit reduces the risk of patients quietly going without medication.

Share with patients: Travoprost Shortage Update: What Patients Need to Know in 2026.

For a comprehensive workflow guide, see: How to Help Your Patients Find Travoprost in Stock: A Provider's Guide.